Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
Respiratory tract infection is a serious condition causing 3 million deaths worldwide every year. Approximately 20-40% of patients with community-acquired pneumonia are hospitalised. Treatment of pneumonia should be initiated as quickly as possible and therefore an early and precise diagnostic is extremely important. Imprecise or delayed diagnosis often results in overconsumption of broad-spectrum antibiotics that contribute to the development of antibiotic resistance. Unspecific symptoms, unsure diagnosis methods and a wait time of up to several days for results challenge a quick and effective diagnosis and treatment of pneumonia. Microbiological analysis of sputum samples is used to identify pathogens causative to pneumonia. However, obtaining specimens of good quality is challenging and affects the sensitivity and specificity of the results. Therefore, the identification of the optimal sputum collecting method is needed to ensure an improved identification process of the pathogen causing pneumonia. The purpose of this study is to determine the most optimal method for obtaining good quality sputum samples when comparing tracheal suction to methods without suction. A more accurate diagnosis will lead to more appropriate antibiotic consumption and will reduce the general development of antibiotic resistance.
Description: Unsuitable (bad quality) measured by microscopy - ≥ 10 squamous epithelial cells and < than 25 polymorphonuclear leucocytes per low power field of view (x10) Suitable (good quality) measured by microscopy - Samples with ≤ 10 squamous epithelial cells and > than 25 polymorphonuclear leucocytes per low power field of view
Measure: Quality of specimen from the lower respiratory tract Time: From collection to culture results - up to 5 daysDescription: Assessed as number of colony forming units per millilitre with a cut off of 10^5 assessed semi-quantitatively as either numerous, some, or few or none.
Measure: Density of microorganisms Time: From collection to culture results - up to 5 daysDescription: The patients are asked about 4 specific symptoms (Cough, Expectoration, Chest pain and Dyspnea). The clinical symptoms are measured as following: yes/no/yes worse than usual. Ten minutes after the intervention they will be asked the same questions with yes/no/worse than before the intervention.
Measure: Patient clinical symptoms Time: Patients are followed before intervention and 10 minutes after interventionDescription: This will be counted by the health professional attending the patient and is the number of breaths per minute in rest. It is assessed by counting the number of times the patients chest rises in a half minute multiplied by 2.
Measure: Respiratory rate Time: Measured twice: Baseline ( at admission) and follow up (10 minutes after intervention)Description: This is measured using a pulse oximetry device - a non-invasive method to measure artieral oxygen saturation level in percentages
Measure: Oxygen saturation Time: Measured twice: Baseline ( at admission) and follow up (10 minutes after intervention)Description: Measured using the Borg Categorical rate 10 scale and a single likert-scale question - 'How does the patient experience the procedure' (only measured after the intervention).
Measure: Patient well-being and experience of procedure Time: Measured twice: Baseline ( at admission) and follow up (10 minutes after intervention)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports